Related Experiment Video

Updated: Sep 3, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.2K

Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer

Antoni Vilaseca1, Maria J Ribal1

  • 1Uro-oncology Unit, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.

European Urology
|July 30, 2022
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.5K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

Related Experiment Videos

Last Updated: Sep 3, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.2K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.5K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

434
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
434

Articles linked to this work by shared authors, journal, and citation graph.

Refining risk stratification after indeterminate urinary cytology: Evidence from Bladder EpiCheck.

Cancer cytopathology·2026

Correction: Pérez et al. Biomarker-Based Nomogram to Predict Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer. Biomedicines 2025, 13, 740.

Biomedicines·2026

Exercise and Physical Activity as Modifiable Risk Factors for Benign Prostatic Hyperplasia: An Update.

Current urology reports·2026

Expert consensus recommendations for the management of biochemical recurrence in prostate cancer: a Delphi study across clinical scenarios.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026

Quality Assessment of Discarded Human Kidneys Using Normothermic Perfusion.

Transplantation direct·2026

A Core Outcome Set for Localized Renal Cell Cancer (L-RCC-COS).

European urology focus·2026

Impact of Treatment Intensification with Abiraterone on Fracture-related Hospitalisation in Newly Diagnosed Prostate Cancer: A Secondary Analysis of Two Randomised Phase 3 Trials Within the STAMPEDE Trial Platform.

European urology·2026

Why Look Further When the Solution Is in Front of You - or Is It? The Value of Confirmatory PSA in Prostate Cancer Screening.

European urology·2026

Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial.

European urology·2026

Hereditary Renal Cancer Syndromes: Redefining Clinical Management in the Era of Precision Medicine.

European urology·2026

PSMA Radio-guided Surgery to Identify Lymph Node Metastases in Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Phase 2 Prospective Study.

European urology·2026

Risk factors and nomogram for predicting central lymph node metastasis in papillary thyroid carcinoma based on gasless transaxillary endoscopic thyroidectomy.

Gland surgery·2026

miR-27b-5p targets RAB27A to regulate exosome secretion and migration of pancreatic cancer cells.

Translational cancer research·2026

Preoperative prediction of extrathyroidal extension in papillary thyroid carcinoma: a nomogram integrating dual-plane ultrasound-based radiomics and clinical features.

Gland surgery·2026

How cholecystectomy and gastrectomy contribute to pancreatic cancer development: a review.

Annals of medicine and surgery (2012)·2026

Development and internal validation of dual overall and cancer-specific survival nomograms for primary spinal and sacropelvic Ewing sarcoma: a population-based study of 346 patients.

Translational cancer research·2026

Development of m6A-related prognostic models for survival in lung squamous cell carcinoma with different PD-L1 expression levels.

Translational cancer research·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us